? San Diego-based Equillium has nabbed an orphan drug designation for EQ001 on the verge of beginning a Phase Ib/II for the immuno-inflammatory drug. Also known as itolizumab, the drug was in-licensed from India?s Biocon, which sells it in the country as a psoriasis treatment. Equillium $EQ, however, is focusing its US clinical work on the prevention and treatment of acute graft-versus-host disease ? a strategy that has allowed it to skip financing rounds and jump str
News
Takeda forecasts $1.7B loss after Shire integration; Flagship’s preclinical biotech Axcella closes IPO with $71M+ haul
? Takeda?s $TAK first set of financial results since consummating its $62 billion acquisition of Shire is in, and it?s giving analysts a negative surprise. Citing costs for integrating the Ireland-based Shire, the Japanese drugmaker forecasts an operat… […]
News
Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches
? Two-and-a-half years after Pfizer stepped up to seed the biotech startup AnTolRx, the pharma giant has stepped in to take their option on an immune tolerance therapy for Type 1 diabetes. Based on the lab work of Francisco Quintana, a professor of neu… […]
Industry News
Lilly, Incyte’s baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO
? Rheumatoid arthritis drug Olumiant?? approved for a narrower-than-expected patient population earlier this year to the dismay of its manufacturer Eli?Lilly $LLY and Incyte $INCY which had blockbuster dreams for the drug?? may be worth its weight in g… […]
